Skip to content

Parkinson's (LRRK2 G2019S)

Not a medical test — for research and educational use only

Yeliztli analyses consumer genotyping-array data (23andMe / AncestryDNA), which is not a clinical-grade test. Results are not diagnostic, are not clinically validated, and must not be used to make medical decisions. Array data is especially unreliable for rare, disease-causing variants. Always confirm any finding with an accredited clinical laboratory and discuss it with a qualified clinician or genetic counsellor before acting on it. See the Intended use & disclaimers page for the details and the evidence behind this warning.

This is an opt-in module

The Parkinson's result stays hidden until you explicitly acknowledge that you want to see it. You choose whether to view or skip it.

This module reports a single, well-studied risk variant: LRRK2 G2019S (rs34637584).

What you'll see

Whether you carry the LRRK2 G2019S variant (one or two copies). The finding emphasises its reduced, age-dependent penetrance. Published age-80 estimates vary by cohort design, ancestry, and modifier burden: recent cohort analyses report roughly 24–49%, with kin-cohort estimates around 25–42.5%. These are population-level estimates, not a personal prediction. By age 80, most carriers in these cohorts had not developed Parkinson's disease. The finding also notes that the variant is more common in Ashkenazi-Jewish and North-African Berber populations.

Good to know

  • By age 80, most carriers in these cohorts had not developed Parkinson's disease, and there is no preventive treatment that depends on this result — which is why it's gated behind explicit consent.
  • A negative result is not reassurance: this is one variant among many genetic and non-genetic contributors. GBA1, another important Parkinson's gene, is deliberately not on the panel because a pseudogene makes it unreliable to genotype from array data.
  • Confirm any positive result with a clinical (CLIA/accredited) laboratory before acting.

Sources